Targeting CTLA4 with “immune checkpoint inhibitors”, such as ipilimumab, an antibody acting on human CTLA4 protein, has emerged as an exciting approach in melanoma treatment, particularly for progressing unresectable cutaneous melanoma in adult humans [52,53,54]. This evidence concerns the gene CTLA4 and cutaneous melanoma.